title: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6.
abstract: OBJECTIVE
  To compare the efficacy and safety of 1-mg and 4-mg doses of preservative-free intravitreal triamcinolone with standard care (grid photocoagulation in eyes without dense macular hemorrhage and deferral of photocoagulation until hemorrhage clears in eyes with dense macular hemorrhage) for eyes with vision loss associated with macular edema secondary to branch retinal vein occlusion (BRVO).
  
  
  METHODS
  Multicenter, randomized clinical trial of 411 participants. Main Outcome Measure Gain in visual acuity letter score of 15 or more from baseline to month 12.
  
  
  RESULTS
  Twenty-nine percent, 26%, and 27% of participants achieved the primary outcome in the standard care, 1-mg, and 4-mg groups, respectively. None of the pairwise comparisons between the 3 groups was statistically significant at month 12. The rates of elevated intraocular pressure and cataract were similar for the standard care and 1-mg groups, but higher in the 4-mg group.
  
  
  CONCLUSIONS
  There was no difference identified in visual acuity at 12 months for the standard care group compared with the triamcinolone groups; however, rates of adverse events (particularly elevated intraocular pressure and cataract) were highest in the 4-mg group. Application to Clinical Practice Grid photocoagulation as applied in the SCORE Study remains the standard care for patients with vision loss associated with macular edema secondary to BRVO who have characteristics similar to participants in the SCORE-BRVO trial. Grid photocoagulation should remain the benchmark against which other treatments are compared in clinical trials for eyes with vision loss associated with macular edema secondary to BRVO. Trial Registration clinicaltrials.gov Identifier: NCT00105027.
authors.affiliation: EMMES Corporation, Rockville, MD 20850, USA.
authors.forename: Ingrid U
authors.initials: IU
authors.lastname: Scott
authors.forename: Michael S
authors.initials: MS
authors.lastname: Ip
authors.forename: Paul C
authors.initials: PC
authors.lastname: VanVeldhuisen
authors.forename: Neal L
authors.initials: NL
authors.lastname: Oden
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Blodi
authors.forename: Marian
authors.initials: M
authors.lastname: Fisher
authors.forename: Clement K
authors.initials: CK
authors.lastname: Chan
authors.forename: Victor H
authors.initials: VH
authors.lastname: Gonzalez
authors.forename: Lawrence J
authors.initials: LJ
authors.lastname: Singerman
authors.forename: Michael
authors.initials: M
authors.lastname: Tolentino
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007267:Injections; D017075:Laser Coagulation; D008269:Macular Edema / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012170:Retinal Vein Occlusion / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D019233:Retreatment; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects; D014786:Vision Disorders / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide